Barclays’s Prothena PRTA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2020
Q2
– Sell
-89,400
Closed -$956K – 6108
2020
Q1
$956K Sell
89,400
-600
-0.7% -$7.27K ﹤0.01% 3002
2019
Q4
$1.42M Buy
90,000
+88,900
+8,082% +$953K ﹤0.01% 3337
2019
Q3
$9K Sell
1,100
-5,600
-84% -$49.7K ﹤0.01% 6374
2019
Q2
$71K Buy
6,700
+3,100
+86% +$31.8K ﹤0.01% 5918
2019
Q1
$44K Sell
3,600
-15,600
-81% -$195K ﹤0.01% 5970
2018
Q4
$198K Sell
19,200
-6,200
-24% -$73.7K ﹤0.01% 4581
2018
Q3
$332K Buy
25,400
+10,700
+73% +$155K ﹤0.01% 4602
2018
Q2
$214K Sell
14,700
-408,700
-97% -$8.07M ﹤0.01% 4663
2018
Q1
$15.5M Buy
423,400
+403,500
+2,028% +$14.7M 0.01% 972
2017
Q4
$746K Buy
+19,900
New +$1.01M ﹤0.01% 3412
2017
Q1
– Sell
-1,200
Closed -$59K – 6927
2016
Q4
$59K Buy
+1,200
New +$66.2K ﹤0.01% 5061
2015
Q1
– Sell
-90
Closed -$2K – 7216
2014
Q4
$2K Hold
90
– – ﹤0.01% 7120
2014
Q3
$2K Hold
90
– – ﹤0.01% 7413
2014
Q2
$2K Hold
90
– – ﹤0.01% 7405
2014
Q1
$3K Sell
90
-218
-71% -$7.03K ﹤0.01% 7337
2013
Q4
$8K Buy
+308
New +$7.72K ﹤0.01% 7063
2013
Q3
– Sell
-322
Closed -$4K – 7563
2013
Q2
$4K Buy
+322
New +$3K ﹤0.01% 7410

Other funds holding PRTA

Barclays's PRTA Position: Q3 2026 in Review

Barclays increased its Prothena (PRTA) stake by 70% in Q3 2026, buying an estimated $236K and bringing the position to 63,989 shares worth $536K. The position accounts for ﹤0.01% of the portfolio, ranked #3421.

Barclays first reported a position in PRTA in Q2 2013 and has held it in 53 quarters since. The position peaked at $5.18M in Q4 2023. 182 funds tracked by Wall St. Rank hold PRTA as of Q3 2026.

  • Barclays held 63,989 shares of Prothena worth $536K as of Q3 2026.
  • Barclays bought 26,366 Prothena shares in Q3 2026, an estimated $236K.
  • Prothena made up ﹤0.01% of Barclays's portfolio in Q3 2026, its #3421 holding.
  • Barclays first reported a position in Prothena in Q2 2013 and has held it in 53 quarters since.
  • Barclays's Prothena position peaked at $5.18M in Q4 2023.
  • 182 funds tracked by Wall St. Rank held Prothena as of Q3 2026.

Based on Barclays's 13F filing for Q3 2026, filed 6 Nov 2026.